Roy Baynes, M.D., Ph.D., has been a member of the board of directors of Travere Therapeutics, Inc. since 2016. He currently serves as executive vice president and chief medical officer of Eikon Therapeutics, Inc. a privately-held biotechnology company. Prior to Eikon Therapeutics, Dr. Baynes served as chief medical officer as well as senior vice president and head of global clinical development at Merck and Co, Inc, where he helped Merck become a leading oncology and global healthcare company. Dr. Baynes also previously served as senior vice president of oncology, inflammation and respiratory therapeutics at Gilead Sciences, Inc., which was preceded by his service at Amgen, Inc. as vice president of global clinical development and therapeutic area head for hematology/oncology. Before joining Amgen, Dr. Baynes was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-designated Comprehensive Cancer Center, at Wayne State University. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. He received his medical degree and doctorate in philosophy from the University of the Witwatersrand in South Africa, and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital. Dr. Baynes has received innumerable awards for his activities as a physician/scientist, and currently also serves on the board of directors at Atara, Inc and Natera, Inc.
© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.